Foreign Drugmakers Now Getting More GMP Warning Letters Than U.S. Firms
This article was originally published in PharmAsia News
Executive Summary
For the first time, this fiscal year FDA seems to be on track to send more warning letters to foreign manufacturers of finished pharmaceuticals and APIs than their domestic counterparts.